Supplementary Figures S1-S9 from VEGF-Targeted Therapy Stably Modulates the Glycolytic Phenotype of Tumor Cells

Supplementary Figures S1-S9. Characterization of cancer cell lines with different metabolic features (S1); Anti-VEGF therapy reduces vascularization and increases necrosis in tumor xenografts (S2); AMPKα1/α2 silencing up-regulates glycolysis and renders tumors less responsive to anti-VEGF therapy (S3); Effects of anti-VEGF therapy on tumor cell proliferation (S4); Expression MCT4 protein in ex vivo cultures of IGROV-1 tumors (S5); Analysis of HIF-1α activity and expression levels of pAKT, c-MYC and pAMPK in ex vivo cultures of IGROV-1 tumors (S6); Bio-energetic analysis of ex vivo cultures of OC316 tumors resistant to anti-VEGF therapy (S7); Selection of highly glycolytic cells in BALB-neuT transgenic mouse model following anti-VEGF therapy (S8); Working hypothesis: Evolutionary dynamics of tumor metabolism (S9).